Evidence map›Paper›PMID 29224778›Full record

ArticleCell2018

Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell.

Jonathan Hoggatt, Pratibha Singh, Tiffany A Tate, Bin-Kuan Chou, Shruti R Datari, Seiji Fukuda, Liqiong Liu, Peter V Kharchenko, Amir Schajnovitz, Ninib Baryawno and 6 more

Abstract read
In one paragraph

Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Endothelial TRIM35-Regulated MMP10 Release Exacerbates Calcification of Vascular Grafts.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jonathan HoggattHarvard Medical School, Cancer Center and Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Electronic address: hoggatt.jonathan@mgh.harvard.edu.
Pratibha SinghDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Tiffany A TateHarvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
Bin-Kuan ChouHarvard Medical School, Cancer Center and Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
Shruti R DatariHarvard Medical School, Cancer Center and Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
Seiji FukudaDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Liqiong LiuDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Peter V KharchenkoHarvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
Amir SchajnovitzHarvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Ninib BaryawnoHarvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Francois E MercierHarvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Joseph BoyerDepartment of Statistical Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA; GlaxoSmithKline, Collegeville, PA 19426, USA.
Jason GardnerGlaxoSmithKline, Collegeville, PA 19426, USA.
Dwight M MorrowGlaxoSmithKline, Collegeville, PA 19426, USA.
David T ScaddenHarvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: david_scadden@harvard.edu.
Louis M PelusDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Electronic address: lpelus@iupui.edu.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Sara K Quinney · 1999 to 2026
$59.3M
Transcriptional and epigenetic heterogeneity of stem/progenitor cellsP01HL131477 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Jason Daniel Buenrostro · 2017 to 2026
$24.6M
Preclinical development of gene-edited human hematopoietic stem cellsU19HL129903 · NHLBI · HARVARD UNIVERSITY · PI NOVAK, RODGER · 2015 to 2019
$11.5M
Project-005U54DK106846 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Reuben Kapur, Karen Elizabeth Pollok · 2015 to 2026
$9.7M
PILOT AND FEASIBILITY STUDIESP30DK049218 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SROUR, EDWARD F · 1999 to 2004
$4.6M
Role of PGE2 and other eicosanoids in hematopoietic stem cell functionR01HL096305 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI PELUS, LOUIS M · 2010 to 2018
$3.5M
Chemokine Induced Hematopoietic Stem Cell MobilizationR01HL069669 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI PELUS, LOUIS M · 2001 to 2009
$2.8M
Statistical methods for analysis of single-cell variabilityR01HL131768 · NHLBI · HARVARD MEDICAL SCHOOL · PI KHARCHENKO, PETER V · 2015 to 2019
$2.4M
Regulation of Osteoblast Function by Megakaryocytes: Key Signaling ProteinsR01AR060332 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI BRUZZANITI, ANGELA, KACENA, MELISSA A · 2011 to 2015
$1.7M
Macrophage Regulation of the Hematopoietic Stem Cell NicheR00HL119559 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HOGGATT, JONATHAN GEORGE · 2015 to 2017
$747k
BD FACSAria SystemS10OD012270 · OD · INDIANA UNIVERSITY INDIANAPOLIS · PI SROUR, EDWARD F · 2013 to 2013
$516k
Macrophage Regulation of the Hematopoietic Stem Cell NicheK99HL119559 · NHLBI · HARVARD UNIVERSITY · PI HOGGATT, JONATHAN GEORGE · 2013 to 2014
$189k
NCI NIH HHS P30 CA082709NHLBI NIH HHS K99 HL119559NHLBI NIH HHS P01 HL131477NHLBI NIH HHS R00 HL119559NHLBI NIH HHS R01 HL069669NHLBI NIH HHS R01 HL096305NHLBI NIH HHS R01 HL131768NHLBI NIH HHS U19 HL129903NIAMS NIH HHS R01 AR060332NIDDK NIH HHS P30 DK049218NIDDK NIH HHS U54 DK106846NIH HHS S10 OD012270
6 · The paper itself

Abstract

Hematopoietic stem cell transplantation is a potential curative therapy for malignant and nonmalignant diseases. Improving the efficiency of stem cell collection and the quality of the cells acquired can broaden the donor pool and improve patient outcomes. We developed a rapid stem cell mobilization regimen utilizing a unique CXCR2 agonist, GROβ, and the CXCR4 antagonist AMD3100. A single injection of both agents resulted in stem cell mobilization peaking within 15 min that was equivalent in magnitude to a standard multi-day regimen of granulocyte colony-stimulating factor (G-CSF). Mechanistic studies determined that rapid mobilization results from synergistic signaling on neutrophils, resulting in enhanced MMP-9 release, and unexpectedly revealed genetic polymorphisms in MMP-9 that alter activity. This mobilization regimen results in preferential trafficking of stem cells that demonstrate a higher engraftment efficiency than those mobilized by G-CSF. Our studies suggest a potential new strategy for the rapid collection of an improved hematopoietic graft.

Indexed as

AdultAnimalsBenzylaminesChemokine CXCL2CyclamsFemaleHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHeterocyclic CompoundsHumansMaleMatrix Metalloproteinase 9MiceMice, Inbred BALB CMice, Inbred C57BLBenzylaminesChemokine CXCL2CyclamsHeterocyclic CompoundsMatrix Metalloproteinase 9plerixaforAMD3100bone marrow transplantationCXCR2CXCR4granulocyte colony-stimulating factorhematopoiesishematopoietic stem cell mobilizationMMP-9neutrophilsstem cell trafficking

Identifiers

PMID29224778
PMCPMC5812290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.